Last reviewed · How we verify
Ruxolitinib 1.5% Cream QD
At a glance
| Generic name | Ruxolitinib 1.5% Cream QD |
|---|---|
| Also known as | INCB018424 |
| Sponsor | CAGE Bio Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus (PHASE2)
- A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ruxolitinib 1.5% Cream QD CI brief — competitive landscape report
- Ruxolitinib 1.5% Cream QD updates RSS · CI watch RSS
- CAGE Bio Inc. portfolio CI